Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou North Avenue, Guangzhou, 1838#510515, China.
J Neuroinflammation. 2022 Sep 1;19(1):214. doi: 10.1186/s12974-022-02571-2.
Brain injury is the main cause of high mortality and disability after successful cardiopulmonary resuscitation (CPR) from sudden cardiac arrest (CA). The transient receptor potential M4 (TRPM4) channel is a novel target for ameliorating blood-brain barrier (BBB) disruption and neuroinflammation. Herein, we tested whether flufenamic acid (FFA), which is reported to block TRPM4 with high potency, could confer neuroprotection against brain injury secondary to CA/CPR and whether its action was exerted by blocking the TRPM4 channel.
Wild-type (WT) and Trpm4 knockout (Trpm4) mice subjected to 10-min CA/CPR were randomized to receive FFA or vehicle once daily. Post-CA/CPR brain injuries including neurologic deficits, survival rate, histological damage, edema formation, BBB destabilization and neuroinflammation were assessed.
In WT mice subjected to CA/CPR, FFA was effective in improving survival and neurologic outcome, reducing neuropathological injuries, attenuating brain edema, lessening the leakage of IgG and Evans blue dye, restoring tight junction protein expression and promoting microglia/macrophages from the pro-inflammatory subtype toward the anti-inflammatory subtype. In comparison to WT mice, Trpm4 mice exhibited less neurologic deficiency, milder histological impairment, more BBB integrity and more anti-inflammatory microglia/macrophage polarization. As expected, FFA did not provide a benefit of superposition compared with vehicle in the Trpm4 mice after CA/CPR.
FFA mitigates BBB breach and modifies the functional status of microglia/macrophages, thereby improving survival and neurologic deficits following CA/CPR. The neuroprotective effects occur at least partially by interfering with the TRPM4 channel in the neurovascular unit. These results indicate the significant clinical potential of FFA to improve the prognosis for CA victims who are successfully resuscitated.
脑损伤是心肺复苏(CPR)成功后心搏骤停(CA)患者高死亡率和高致残率的主要原因。瞬时受体电位 M4(TRPM4)通道是改善血脑屏障(BBB)破坏和神经炎症的新靶点。在此,我们测试了氟芬那酸(FFA)是否能对 CA/CPR 继发的脑损伤提供神经保护作用,FFA 据报道能高亲和力阻断 TRPM4,以及其作用是否通过阻断 TRPM4 通道发挥。
野生型(WT)和 Trpm4 敲除(Trpm4)小鼠接受 10 分钟 CA/CPR 后,随机接受 FFA 或载体每日一次。评估 CA/CPR 后的脑损伤,包括神经功能缺损、存活率、组织学损伤、水肿形成、BBB 失稳和神经炎症。
在接受 CA/CPR 的 WT 小鼠中,FFA 可有效改善存活率和神经功能预后,减少神经病理学损伤,减轻脑水肿,减少 IgG 和 Evans 蓝染料的渗漏,恢复紧密连接蛋白的表达,并促进小胶质细胞/巨噬细胞从促炎表型向抗炎表型转化。与 WT 小鼠相比,Trpm4 小鼠表现出较轻的神经缺损、较轻的组织学损伤、更好的 BBB 完整性和更多的抗炎小胶质细胞/巨噬细胞极化。如预期的那样,与 CA/CPR 后的 WT 小鼠相比,FFA 与载体相比并未提供叠加益处。
FFA 减轻 BBB 破裂并改变小胶质细胞/巨噬细胞的功能状态,从而改善 CA/CPR 后的存活率和神经功能缺损。神经保护作用至少部分通过干扰神经血管单元中的 TRPM4 通道发生。这些结果表明,FFA 具有显著的临床潜力,可以改善成功复苏的 CA 患者的预后。